Comparison of tomographic and planar imaging for the evaluation of thrombolytic therapy in acute myocardial infarction using pre- and post-treatment myocardial scintigraphy with technetium-99m sestamibi
- PMID: 1829568
- DOI: 10.1016/0002-8703(91)90752-4
Comparison of tomographic and planar imaging for the evaluation of thrombolytic therapy in acute myocardial infarction using pre- and post-treatment myocardial scintigraphy with technetium-99m sestamibi
Abstract
Pre- and post-treatment myocardial scintigraphy with technetium-99m hexakis 2-methoxy-isobutyl-isonitrile (Tc-99m sestamibi) was performed in patients who underwent thrombolytic therapy for acute myocardial infarction comparing planar imaging and single-photon emission computed tomography (SPECT). Twenty-one patients were injected with Tc-99m sestamibi before thrombolytic treatment. SPECT and planar imaging were acquired after completion of the treatment. The scintigraphy was repeated 5 days later in 20 subjects. Planar and SPECT studies were evaluated using an uptake score. Patients were divided according to the status of the infarct-related vessel (patent in 13 patients, group 1, and occluded in seven, group 2) and to the presence of functional recovery in serial echocardiographic controls (present in 10 patients, group A, and absent in 10, group B). The scintigraphic defect extent in the 5-day images correlated with the enzymatic infarct size: SPECT: r = 0.75, p less than 0.0002; planar: r = 0.68, p less than 0.002. The decrease of the uptake defects correlated with the reduction of the left ventricular wall asynergy (admission versus 1 month echocardiogram): SPECT: r = 0.92, p less than 0.000001; planar: r = 0.82, p less than 0.00001. The percent decrease of the uptake defects was significantly higher in patients in group 1 and group A compared with group 2 and, respectively, group B--SPECT: group 1: 51.4 +/- 27.7 versus group 2: 13.1 +/- 8.6, p less than 0.02; group A: 64.2 +/- 15.3 versus group B: 11.9 +/- 8.1, p less than 0.0002; planar group 1: 41 +/- 30.4 versus group 2: 7.7 +/- 6.2, p less than 0.05; group A: 52.5 +/- 24.3 versus group B: 6.1 +/- 6, p less than 0.0002. This study confirms the reliability of pre- and post-treatment myocardial scintigraphy with Tc-99m sestamibi for evaluating the outcome of thrombolytic treatment in myocardial infarction. The results seems slightly more accurate using SPECT, but a simple three-view planar study also gives useful data.
Similar articles
-
[Ealuation of thrombolytic treatment of acute myocardial infarct using myocardial scintigraphy with Tc-99-MIBI. Immediate results and follow-up after one year].G Ital Cardiol. 1990 Nov;20(11):987-96. G Ital Cardiol. 1990. PMID: 2090556 Italian.
-
Single photon emission computed tomography with technetium-99m hexakis 2-methoxyisobutyl isonitrile in acute myocardial infarction before and after thrombolytic treatment: assessment of salvaged myocardium and prediction of late functional recovery.J Am Coll Cardiol. 1990 Feb;15(2):301-14. doi: 10.1016/s0735-1097(10)80053-1. J Am Coll Cardiol. 1990. PMID: 2137147
-
[Late thrombolysis in acute myocardial infarct. Demonstration of myocardial tissue salvage by the assessment of pre- and post-thrombolytic perfusion and left ventricular function].G Ital Cardiol. 1994 Nov;24(11):1359-70. G Ital Cardiol. 1994. PMID: 7828789 Italian.
-
Myocardial perfusion imaging with technetium-99m sestamibi SPECT in the evaluation of coronary artery disease.Am J Cardiol. 1990 Oct 16;66(13):55E-62E. doi: 10.1016/0002-9149(90)90613-6. Am J Cardiol. 1990. PMID: 2145748 Review.
-
Tc-99m SPECT sestamibi for the measurement of infarct size.J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):321-31. doi: 10.1177/1074248411414906. J Cardiovasc Pharmacol Ther. 2011. PMID: 21821535 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical